Drug Trial Radar · NCT06639282
Repurposing Siponimod for Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Aug 26, 2025
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- St. Joseph's Hospital and Medical Center, PhoenixAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Texas Tech University Health Sciences Center; Arizona State University; National Institute on Aging (NIA); Novartis; Laboratory Corporation of America
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.
Conditions
- Alzheimer Disease
- Mild Alzheimer Disease
- MCI With Increased Risk for Alzheimer Disease
- Cognitive Impairment, Mild
Interventions
SiponimodDrug
Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
PlaceboDrug
A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs)Time frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.